Evidence map›Paper›PMID 25425469›Full record

ArticleExperimental dermatology2015

CpGB DNA activates dermal macrophages and specifically recruits inflammatory monocytes into the skin.

Allison L Mathes, Lisa Rice, Alsya J Affandi, Michael DiMarzio, Ian R Rifkin, Giuseppina Stifano, Romy B Christmann, Robert Lafyatis

Abstract read
In one paragraph

Article in Experimental dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Nanocomplexes of doxorubicin and DNA fragments for efficient and safe cancer chemotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2023
    Article
  3. scDual-Seq ofFrontiers in immunology · 2023
    Article
  4. Article
  5. Update on macrophages and innate immunity in scleroderma.Current opinion in rheumatology · 2015
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Allison L MathesRheumatology Section, Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
Lisa Rice
Alsya J Affandi
Michael DiMarzio
Ian R Rifkin
Giuseppina Stifano
Romy B Christmann
Robert Lafyatis
Boston University · USUtrecht University · NL

Funding

Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesisP50AR060780 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DOMSIC, ROBYN THERESE · 2011 to 2021
$14.9M
RESEARCH TRAINING IN IMMUNOLOGYT32AI007309 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GUMMULURU, SURYARAM · 1988 to 2024
$7.4M
Rheumatic Diseases Research Core CentersP30AR061271 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI WHITFIELD, MICHAEL L · 2011 to 2015
$3.1M
Innate immunity in dermal fibrosis and systemic sclerosisR01AR051089 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LAFYATIS, ROBERT A. · 2005 to 2015
$2.8M
RHEUMATOLOGY TRAINING GRANTT32AR007598 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FELSON, DAVID TOBIN · 1997 to 2018
$2.3M
NIAID NIH HHS 5T32 AI007309NIAID NIH HHS T32 AI007309NIAMS NIH HHS 1P50AR060780NIAMS NIH HHS 2R01AR051089NIAMS NIH HHS 5P30AR061271NIAMS NIH HHS P30 AR061271NIAMS NIH HHS P50 AR060780NIAMS NIH HHS R01 AR051089NIAMS NIH HHS T32 AR007598
6 · The paper itself

Abstract

Toll-like receptor 9 (TLR9) drives innate immune responses after recognition of foreign or endogenous DNA containing unmethylated CpG motifs. DNA-mediated TLR9 activation is highly implicated in the pathogenesis of several autoimmune skin diseases, yet its contribution to the inflammation seen in these diseases remains unclear. In this study, TLR9 ligand, CpGB DNA, was administered to mice via a subcutaneous osmotic pump with treatment lasting 1 or 4 weeks. Gene expression and immunofluorescence analyses were used to determine chemokine expression and cell recruitment in the skin surrounding the pump outlet. CpGB DNA skin treatment dramatically induced a marked influx of CD11b+ F4/80+ macrophages, increasing over 4 weeks of treatment, and induction of IFNγ and TNFα expression. Chemokines, CCL2, CCL4, CCL5, CXCL9 and CXCL10, were highly induced in CpGB DNA-treated skin, although abrogation of these signalling pathways individually did not alter macrophage accumulation. Flow cytometry analysis showed that TLR9 activation in the skin increased circulating CD11b+ CD115+ Ly6C(hi) inflammatory monocytes following 1 week of CpGB DNA treatment. Additionally, skin-resident CD11b+ cells were found to initially take up subcutaneous CpGB DNA and propagate the subsequent immune response. Using diphtheria toxin-induced monocyte depletion mouse model, gene expression analysis demonstrated that CD11b+ cells are responsible for the CpGB DNA-induced cytokine and chemokine response. Overall, these data demonstrate that chronic TLR9 activation induces a specific inflammatory response, ultimately leading to a striking and selective accumulation of macrophages in the skin.

Indexed as

CpG IslandsMacrophage ActivationAdministration, CutaneousAnimalsCD11b AntigenChemokinesDiphtheria ToxinDNAFlow CytometryGene Expression ProfilingGene Expression RegulationImmunohistochemistryInflammationInterferon-gammaLigandsMacrophagesCD11b AntigenChemokinesDiphtheria ToxinDNAInterferon-gammaLigandsToll-Like Receptor 9cell traffickingchemokinesinflammationmonocytes/macrophagesskin

Identifiers

PMID25425469
PMCPMC4474603
OpenAlexW2116783743

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.